Yakhak Hoeji最新文献_第3页

Trends in Pharmaceutical Market Structure and Generic Drug Utilization in the Korean National Health Security System (2007-2017) 2007-2017年韩国医疗保障体系药品市场结构及仿制药利用趋势

Yakhak Hoeji Pub Date : 2023-06-30 DOI: 10.17480/psk.2023.67.3.205

Suhyun Jang, S. Jang

{"title":"Trends in Pharmaceutical Market Structure and Generic Drug Utilization in the Korean National Health Security System (2007-2017)","authors":"Suhyun Jang, S. Jang","doi":"10.17480/psk.2023.67.3.205","DOIUrl":"https://doi.org/10.17480/psk.2023.67.3.205","url":null,"abstract":"We aimed to analyze the market structure and changes in the market share of new drugs, original drugs, and generic drugs in the pharmaceutical market over the past ten years. We utilized national health insurance claims data, including both national health insurance and medical aid, from 2007 to 2017 to establish pharmaceutical expenditure and usage data. The drugs are categorized into new drugs, original drugs (expired patents), and generic drugs. Furthermore, we classified the original drugs as single-source and multi-source original drugs based on whether generic drugs had entered the market. Market share is calculated based on the volume and value of drugs in each category. The results indicate that the total pharmaceutical expenditure increased by 1.75 times, from 10.4 trillion Korean won (KRW) in 2007 to 18.2 trillion KRW in 2017. The number of claimed ingredients and drug items also increased during the same period. In 2017, the market share of new drugs accounted for 10.3% of the total pharmaceutical expenditure, while original drugs and generic drugs accounted for 45.9% and 43.8%, respectively. The study reveals a slight decline in the market share of generics in the decade. Further sub-analyses based on formulation, medical center types, and the number of generic drugs provide additional insights into the market dynamics. These findings contribute to understanding the trends and implications of pharmaceutical expenditure and the role of generics in achieving sustainable development in national health insurance.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80541510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of International Status on Digital Health Policies in the Health Care Sector 卫生保健部门数字卫生政策国际现状调查

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.85

K. Cho, Kwang Joon Kim

引用次数: 0

Review of Court’s Judicial Precedents for Community Pharmacists’ Misconducts 法院对社区药师不当行为司法判例的评析

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.94

Seong Yeon Kim, Hyun Jin Kim, Sol-Ah Park, Hyunjoo Sohn

{"title":"Review of Court’s Judicial Precedents for Community Pharmacists’ Misconducts","authors":"Seong Yeon Kim, Hyun Jin Kim, Sol-Ah Park, Hyunjoo Sohn","doi":"10.17480/psk.2023.67.2.94","DOIUrl":"https://doi.org/10.17480/psk.2023.67.2.94","url":null,"abstract":"Registered pharmacists are required to comply with current laws related to pharmacist practice. This study investigated the precedents of community pharmacists’ misconduct. The cases disclosed to the public on the Korean court’s websites (Comprehensive Legal Information website and Major Court Rulings website) were searched in April 19, 2021, using a keyword “pharmacist”. The selection criteria included case pronounced after July 2000 (implementation of the separation of prescription and dispensing), case that pharmacists was the plaintiffs or the defendants, and case that violated the Pharmaceutical Affairs Act or the National Health Insurance Act. For nineteen cases finally selected which satisfied with eligibility criteria, detailed information for each case were collected from the websites. Based on the provisions of related laws, misconducts of those cases were classified into seven categories: Four cases of license lending, seven cases of illegal drug dispensing and sales, two cases of collusion with medical institutions, two cases of violations of medication guidance obligations, one case of indiscriminate sales of medicines liable to misuse or abuse, two cases of unfair customer inducements, and one case of rebate and undue pressure exercise. The most frequent misconduct types were unfair receipts of medical care benefits and dispensing or sale of medicines by unqualified persons. Learning about the precedents shown in this study is expected to be an guide for individual pharmacists to increase their sensitivity to ethics and compliance with the laws and to be careful about the possible violations in advance.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78431394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacist’s Intervention Activities for Drug-related Problems in a Community Pharmacy 社区药房药师对药物相关问题的干预活动

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.128

Jin-Hyang Kim, Eun-Suk Kim, Hong-Ju Na, Yu-Ri Lee, Hee-Jo Lee, Il-Ho Park, Jae-Wook Yang, Hye-Lin Kim

{"title":"Pharmacist’s Intervention Activities for Drug-related Problems in a Community Pharmacy","authors":"Jin-Hyang Kim, Eun-Suk Kim, Hong-Ju Na, Yu-Ri Lee, Hee-Jo Lee, Il-Ho Park, Jae-Wook Yang, Hye-Lin Kim","doi":"10.17480/psk.2023.67.2.128","DOIUrl":"https://doi.org/10.17480/psk.2023.67.2.128","url":null,"abstract":"Community pharmacists have contributed to safe and effective drug treatment for patients by performing appropriate intervention activities to solve the drug-related problems (DRPs). This study aims to investigate the current status and evaluate interventions performed in community pharmacies. We evaluated DRP and pharmacist intervention activity (PIA) data obtained from a community pharmacy between August 9, 2021 and October 15, 2021 (10 weeks). Problems and causes of DRPs were classified according to Pharmaceutical Care Network Europe (PCNE) criteria, while PIAs were assessed by intervention types and conducted time-points. Economic outcomes from PIA were also estimated by cost avoidance and cost saving. During the ten-week period, a total of 6,576 prescriptions were submitted, and 754 cases of intervention were conducted. Among 754 PIA cases, 48.8% of them were performed via DUR alert, but 51.2% of PIAs were initiated via counseling or inspection by pharmacist without DUR alert. The acceptance rate of PIA by patients and prescription doctors reached to 93.4%. The net benefit cost converted to annual cost was estimated at ₩5,674,032. Various PIAs in community pharmacies run at various points from the moment the patient is prescribed to the end of treatment. To properly evaluate the clinical and cost-effective value for PIA of community pharmacy, constructing a database of information on DRPs and PIAs must be preceded.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74207216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to Safe and Effective Medication for Individuals with Sensory Impairment: A Systematic Literature Review 对感觉障碍患者进行安全有效药物治疗的障碍:系统文献综述

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.103

Jong-wook Lee, Nayoung Kwak, Euna Han, Hye-Young Kang

{"title":"Barriers to Safe and Effective Medication for Individuals with Sensory Impairment: A Systematic Literature Review","authors":"Jong-wook Lee, Nayoung Kwak, Euna Han, Hye-Young Kang","doi":"10.17480/psk.2023.67.2.103","DOIUrl":"https://doi.org/10.17480/psk.2023.67.2.103","url":null,"abstract":"Visual impairment (VI) and hearing impairment (HI) are common disabilities whose prevalence increases with age, potentially presenting a major challenge in the future. Identifying the types of obstacles which they encounter during drug administration is essential to improve health outcomes. This systematic literature review aimed to identify types of medication barriers encountered by individuals with VI or HI to improve their health outcomes. Combination of keywords indicating VI or HI, barrier, challenge, or difficulty, and drug or medication were used to identify potential studies up to May 31, 2021, from Ovid Medline, Embase, and Cochrane. Overall, 20 and 17 articles met the predefined eligibility criteria for VI and HI, respectively. Individuals with VI were found to encounter difficulties in the entire process of pharmaceutical therapy, including drug identification, medication management, access to pharmacies, medication instructions, drug information (labeling), and communication. Individuals with HI were found to experience challenges in communication, health literacy, and negative experiences and emotions toward doctors/pharmacists. The drug management needs of individuals with VI and HI remain unmet. For safe and effective medication in individuals with VI and HI, it is essential to establish practical solutions, such as providing identification tools for tablets for those with VI, deploying sign language interpreters at designated healthcare institutions and pharmacies for individuals with HI, utilizing novel technologies, including audio prescription labeling systems or mobile applications, and providing education for both healthcare providers and individuals with disabilities to improve their partnership in drug therapy.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89267065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Status of Comprehensive Medication Management in Long-term Care Facilities: Focused on Australia, Canada, the United Kingdom and the United States 长期护理机构综合用药管理现状:以澳大利亚、加拿大、英国和美国为研究对象

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.118

Hyunjin Cho, Taehyun Kim, Suhyun Jang, Hee-Jin Kang, Ju-Yeun Lee, E. Bae, Joohyun Lee, Young-Mi Ah, Hyekyung Park, S. Jang

{"title":"Current Status of Comprehensive Medication Management in Long-term Care Facilities: Focused on Australia, Canada, the United Kingdom and the United States","authors":"Hyunjin Cho, Taehyun Kim, Suhyun Jang, Hee-Jin Kang, Ju-Yeun Lee, E. Bae, Joohyun Lee, Young-Mi Ah, Hyekyung Park, S. Jang","doi":"10.17480/psk.2023.67.2.118","DOIUrl":"https://doi.org/10.17480/psk.2023.67.2.118","url":null,"abstract":"Polypharmacy and potentially inappropriate medication use have increased among the residents of long-term care facilities (LTCF). Nevertheless, Comprehensive Medication Management (CMM) for LTCF residents was not implemented in Korea. The United Kingdom, Canada, the United States, and Australia have already introduced CMM for managing drug-related problems in LTCF. This study discussed the implications of developing the CMM service for LTCF residents in Korea by reviewing the system of these countries. The contents and requirements of CMM are investigated through relevant papers and official reports of the public institution of each country. The CMM service of these countries is regularly conducted based on their system and laws. In Canada, there are no additional requirements such as special education and qualifications for pharmacists providing CMM. But in other countries, it is preferred that pharmacists providing CMM are geriatric pharmacists or take the education that is equivalent to them. In addition, all these countries utilize national computer networks or electronic healthcare records that are used for executing CMM and for sharing with other medical experts, and then they are retained as official medical records. It is necessary to consider the system of other countries when introducing the CMM service for LTCF residents in Korea.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88465272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emicizumab Prophylaxis in Patients with Hemophilia A Undergoing Immune Tolerance Induction Therapy: A Systematic Review 接受免疫耐受诱导治疗的A型血友病患者的Emicizumab预防:系统综述

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.75

A. Kim, Yoon Cho, Seoyoon Kang, Y. Park, H. Baek, Hankil Lee

{"title":"Emicizumab Prophylaxis in Patients with Hemophilia A Undergoing Immune Tolerance Induction Therapy: A Systematic Review","authors":"A. Kim, Yoon Cho, Seoyoon Kang, Y. Park, H. Baek, Hankil Lee","doi":"10.17480/psk.2023.67.2.75","DOIUrl":"https://doi.org/10.17480/psk.2023.67.2.75","url":null,"abstract":"Objective: The use of Emicizumab, a novel agent in hemophilia A, in patients with Hemophilia A undergoing immune tolerance induction (ITI) have been currently evolving in overseas. Here, we aimed to evaluate the real-world use and conceptual study of emicizumab use during ITI in patients with Hemophilia A. Methods: We searched PubMed, Embase, and Cochrane Library databases to perform systematic review according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Search terms include ‘hemophilia‘, ‘immune tolerance and ‘Emicizumab’. Hemophilia other than hemophilia A, studies with no relevant outcomes, emicizumab use other than during ITI were excluded. Results: Among 419 relevant studies, ten eligible studies were included in this review. Six studies reported real-world prophylactic use of emicizumab during ITI, and total of nineteen subjects, including overlapping patients, were evaluated. Other four studies reported conceptual study design of emicizumab in patients with hemophilia A undergoing ITI. Majority of study set the dose of emicizumab as 1.5mg/kg weekly or 3.0mg/kg bi-weekly after a loading dose of 3.0mg/kg for 4 weeks. In real-world prophylactic use studies, ITI outcome, inhibitor recurrence, antibody titer, adverse events, and FVIII activity were evaluated as outcomes. Conclusion: This study identified the current status of emicizumab use and made evidence for the applicability of emicizumab in patients with hemophilia A undergoing ITI.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84383198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of Digital Therapeutics and the Role of Pharmacist 数字治疗学的特点与药师的角色

Yakhak Hoeji Pub Date : 2023-04-30 DOI: 10.17480/psk.2023.67.2.67

Ji Min Choi, Kwang Joon Kim

引用次数: 0

Detecting Drug Interaction Signal of Concomitant Use of Warfarin and Statins Using Korea Adverse Event Reporting System Database 利用韩国不良事件报告系统数据库检测华法林和他汀类药物同时使用的药物相互作用信号

Yakhak Hoeji Pub Date : 2023-02-28 DOI: 10.17480/psk.2023.67.1.15

Heehyun Won, Hyunyoung Choi, Suvin Park, N. Choi

{"title":"Detecting Drug Interaction Signal of Concomitant Use of Warfarin and Statins Using Korea Adverse Event Reporting System Database","authors":"Heehyun Won, Hyunyoung Choi, Suvin Park, N. Choi","doi":"10.17480/psk.2023.67.1.15","DOIUrl":"https://doi.org/10.17480/psk.2023.67.1.15","url":null,"abstract":"The increase in polypharmacy in elderly patients is recognized as a serious health, economic, and social problem. Warfarin and statins are commonly co-administered to cardiovascular disease patients. However, there is a potential risk of drug-drug interaction (DDI). The objective of this study was to detect signals of adverse events (AEs) for DDI after concomitant use of warfarin and statins using Korea adverse events reporting system (KAERS) database. KAERS database from January 2016 to December 2020 was used. Omega (Ω) shrinkage measure model and Chi-square statistics model were used to calculate the criteria for detecting AEs signal resulting from concomitant use of warfarin and statins. Three indices were used to define signals: Ω025 (frequentist) >0, Ω025 (Bayesian) >0, and >2. Detected signals were compared with AEs listed on the drug label in Korea, Micromedex, and SIDER for warfarin and statins, respectively. Twenty-seven AEs on reports of concomitant use were detected as signals. Of 27 detected signals, 11 signals, including breath odour not otherwise specified (NOS), depersonalization, gastrointestinal neoplasm NOS, pleural effusion, medical device complication, menopausal symptoms, oedema cerebral, osteitis, prostatic hyperplasia, lipoma, and skin hypertrophy, were not listed on drug label. We identified signals for concomitant use of warfarin and statins. Careful monitoring and further pharmacoepidemiological studies of DDI associated with new signals using other databases are needed.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79928189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Indirubin on Morphology Changes and mRNA Expression of Cytokines in LPS-induced RAW264.7 靛玉红对lps诱导RAW264.7细胞因子mRNA表达及形态学变化的影响

Yakhak Hoeji Pub Date : 2023-02-28 DOI: 10.17480/psk.2023.67.1.51

Y. Hwang, Jae seon Kang

{"title":"Effect of Indirubin on Morphology Changes and mRNA Expression of Cytokines in LPS-induced RAW264.7","authors":"Y. Hwang, Jae seon Kang","doi":"10.17480/psk.2023.67.1.51","DOIUrl":"https://doi.org/10.17480/psk.2023.67.1.51","url":null,"abstract":"This study was conducted to investigate the regulatory effect of Indirubin on LPS-induced inflammation in macrophage. The morphologic changes were shown as widened cytoplasm or biased nucleus from the center of the cell when LPS activated macrophage. The changes in inflammation activity were also estimated with mRNA levels of cytokines under time elapse at 2, 4, 8, 12, and 24 hours after the 10 ng/mL LPS treatment. By measuring those proinflammatory (TNF-α, IL-1β) and anti-inflammatory (IL-10) cytokines at each time set, the relationship between morphologic change and inflammation activity was compared. The highest pro-inflammatory mRNA expression was observed at 2 hours after the LPS treatment, and this was inhibited by those Indirubin standard (Indirubin) and Chungdae extract (CDEX). The mRNA expression level in LPS treated cell was markedly reduced at 8 hours as well as the other groups. However, IL-10, the anti-inflammatory cytokines was not affected by those treatments. The results suggested that the level of inflammation related changes as time elapsed. The current observation that both Indirubin and CDEX are able to inhibit LPS-induced inflammation by reducing the production of inflammatory cytokines. Moreover, the current observation suggested that estimating anti-inflammatory effects should include time-dependent measurements as biomarkers.","PeriodicalId":23923,"journal":{"name":"Yakhak Hoeji","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86607819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0